MedPath

Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis

Efficacy of Nerve Block Versus Botox in Chronic Migraine Management

Not Applicable
Recruiting
Conditions
Chronic Migraine
Chronic Migraine, Headache
Interventions
Procedure: Nerve Block Injections
First Posted Date
2024-11-12
Last Posted Date
2024-11-12
Lead Sponsor
Zagazig University
Target Recruit Count
64
Registration Number
NCT06684249
Locations
🇪🇬

Zagazig University, Faculty of Medicine, Zagazig, El-Sharkia, Egypt

Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture

Phase 1
Recruiting
Conditions
Skin Aging
Skin Wrinkling
Interventions
Drug: PrabotulinumtoxinA-Xvfs
Drug: saline solution (placebo)
First Posted Date
2024-09-20
Last Posted Date
2024-09-20
Lead Sponsor
Kalpna Kay Durairaj, MD, FACS
Target Recruit Count
20
Registration Number
NCT06604832
Locations
🇺🇸

K. Kay Durairaj, MD, A Medical Corp., Pasadena, California, United States

Effect of Botulinum Toxin on Selective Motor Control and Pain in Diplegic Cerebral Palsy

Phase 4
Recruiting
Conditions
Cerebral Palsy Spastic Diplegia
Interventions
Other: Conventional Physical Therapy
First Posted Date
2024-09-04
Last Posted Date
2025-05-07
Lead Sponsor
Gaziosmanpasa Research and Education Hospital
Target Recruit Count
40
Registration Number
NCT06583343
Locations
🇹🇷

Gaziosmanpasa Research and Education Hospital, Istanbul, Gaziosmanpaşa, Turkey

Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction

Phase 2
Recruiting
Conditions
Erectile Dysfunction With Diabetes Mellitus
Interventions
First Posted Date
2024-09-04
Last Posted Date
2024-12-03
Lead Sponsor
Aswan University Hospital
Target Recruit Count
32
Registration Number
NCT06583590
Locations
🇪🇬

Aswan University-Faculty of Medicine, Aswan, Aswan Governorate, Egypt

A Multicentre, Randomised, Single-blind, Controlled Protocol to Evaluate the Efficacy of Early Administration of Botulinum Toxin for Primary Midline Closure in Patients With Open Abdomen.

Phase 4
Not yet recruiting
Conditions
Botulinum Toxin Type A
Clinical Trial
Abdominal Wall
Open Abdomen
Interventions
First Posted Date
2024-08-15
Last Posted Date
2024-08-15
Lead Sponsor
Instituto de Investigación Hospital Universitario La Paz
Target Recruit Count
50
Registration Number
NCT06556030

OnaBotulinumtoxin-A in Chronic Migraine Patients With Short or Long Disease History (the BACH Study)

Recruiting
Conditions
Migraine
Interventions
First Posted Date
2024-08-05
Last Posted Date
2024-08-05
Lead Sponsor
Fondazione Policlinico Universitario Campus Bio-Medico
Target Recruit Count
115
Registration Number
NCT06537700
Locations
🇮🇹

Università Politecnica delle Marche, Ancona, Italy

🇮🇹

IRCCS Istituto Auxologico Italiano, Milano, Italy

🇮🇹

Università Studi dell'Aquila, L'Aquila, Italy

and more 3 locations

Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery

Phase 2
Not yet recruiting
Conditions
Head Neck Cancer
Xerostomia Following Radiotherapy
Interventions
First Posted Date
2024-07-31
Last Posted Date
2024-07-31
Lead Sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Target Recruit Count
50
Registration Number
NCT06530524
Locations
🇨🇦

McGill University, Montreal, Quebec, Canada

Thoracic Sympathetic Ganglion Block With Botulinum Toxin Type A

Not Applicable
Not yet recruiting
Conditions
Complex Regional Pain Syndromes
Interventions
First Posted Date
2024-06-24
Last Posted Date
2024-06-26
Lead Sponsor
Seoul National University
Target Recruit Count
78
Registration Number
NCT06470581

Use of Botulinum Toxin A in Direct Eyebrow Lift Scar

Phase 2
Recruiting
Conditions
Skin Scarring
Eyebrow Ptosis
Interventions
First Posted Date
2024-06-18
Last Posted Date
2024-06-18
Lead Sponsor
University of Sao Paulo
Target Recruit Count
40
Registration Number
NCT06465056
Locations
🇧🇷

University of São Paulo (Clinical Hospital), São Paulo, Brazil

🇧🇷

Ophthalmology Dept. University of Sao Paulo General Hospital, Sao Paulo, Brazil

Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides

Phase 4
Not yet recruiting
Conditions
Wrinkle
Interventions
First Posted Date
2024-06-07
Last Posted Date
2024-07-30
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Target Recruit Count
240
Registration Number
NCT06448676
© Copyright 2025. All Rights Reserved by MedPath